- Home
- HBAN vs DGX Comparison
HBAN vs DGX Comparison
Compare HBAN & DGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HBAN | DGX |
|---|---|---|
| Founded | 1866 | 1967 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.4B | 23.1B |
| IPO Year | N/A | 1996 |
Fundamental Metrics
Financial Performance| Metric | HBAN | DGX |
|---|---|---|
| Price | $15.43 | $197.73 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 17 | 13 |
| Target Price | $19.38 | ★ $208.62 |
| AVG Volume (30 Days) | ★ 25.8M | 630.1K |
| Earning Date | 04-16-2026 | 04-21-2026 |
| Dividend Yield | ★ 3.99% | 1.75% |
| EPS Growth | N/A | ★ 13.78 |
| EPS | N/A | ★ 8.75 |
| Revenue | N/A | ★ $11,035,000,000.00 |
| Revenue This Year | $51.26 | $7.53 |
| Revenue Next Year | $8.90 | $3.77 |
| P/E Ratio | ★ $12.87 | $22.43 |
| Revenue Growth | N/A | ★ 11.78 |
| 52 Week Low | $11.92 | $157.20 |
| 52 Week High | $19.44 | $213.50 |
Technical Indicators
Market Signals| Indicator | HBAN | DGX |
|---|---|---|
| Relative Strength Index (RSI) | 36.96 | 47.30 |
| Support Level | $15.14 | $176.61 |
| Resistance Level | $16.28 | $205.00 |
| Average True Range (ATR) | 0.39 | 4.30 |
| MACD | 0.04 | -0.87 |
| Stochastic Oscillator | 35.86 | 39.60 |
Price Performance
Historical ComparisonAbout HBAN Huntington Bancshares Incorporated
Huntington is a regional US bank with over $200 billion in assets and has a large presence, particularly in the Midwestern market. It offers a full suite of consumer deposit and lending services, along with commercial services focused on payments, investment management, capital markets, equipment financing, treasury management, and other common banking services.
About DGX Quest Diagnostics Incorporated
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the US. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.